随着肽治疗活性的发现，它们因其特异性靶向、低毒性和高选择性潜力而成为一类有前途的抗癌药物。特别是，随着肽-药物偶联物进入临床，靶向肽与传统化疗药物或细胞毒药物的偶联将成为癌症治疗的新方向。为了促进癌症治疗肽的药物开发，我们构建了 DCTPep，一个新颖、开放、综合的癌症治疗肽数据库。除了传统的抗癌肽（ACP）外，肽库还包括与癌症治疗相关的肽。这些数据是从已发表的研究文章、专利和其他蛋白质或肽数据库中手动收集的。药物库数据包括临床研究和/或批准的与癌症治疗相关的肽类药物，主要来自不同国家和地区的药品监管部门和组织的门户网站。 DCTPep 共有 6214 个条目，我们相信 DCTPep 将为未来癌症治疗肽的设计和筛选做出贡献。© 2024。作者。

With the discovery of the therapeutic activity of peptides, they have emerged as a promising class of anti-cancer agents due to their specific targeting, low toxicity, and potential for high selectivity. In particular, as peptide-drug conjugates enter clinical, the coupling of targeted peptides with traditional chemotherapy drugs or cytotoxic agents will become a new direction in cancer treatment. To facilitate the drug development of cancer therapy peptides, we have constructed DCTPep, a novel, open, and comprehensive database for cancer therapy peptides. In addition to traditional anticancer peptides (ACPs), the peptide library also includes peptides related to cancer therapy. These data were collected manually from published research articles, patents, and other protein or peptide databases. Data on drug library include clinically investigated and/or approved peptide drugs related to cancer therapy, which mainly come from the portal websites of drug regulatory authorities and organisations in different countries and regions. DCTPep has a total of 6214 entries, we believe that DCTPep will contribute to the design and screening of future cancer therapy peptides.© 2024. The Author(s).